Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling crosstalk

Blood

Volumn 99, Issue 3, 2002, Pages 1014-1022

  Zhu, Qi ^a,b,c   Zhang, Ji Wang ^a,b,c   Zhu, Hai Qing ^a,b,c   Shen, Yu Lei ^a,b,c   Flexor, Maria ^a,b,c   Jia, Pei Ming ^a,b,c   Yu, N ^a,b,c   Cai, Xun ^a,b,c   Waxman, Samuel ^a,b,c   Lanotte, Michel ^a,b,c   Chen, Sai Juan ^a,b,c   Chen, Zhu ^a,b,c   Tong, Jian Hua ^a,b,c  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SAINT LOUIS HOSPITAL   (France)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 (4 CHLOROPHENYLTHIO) CYCLIC AMP; ARSENIC TRIOXIDE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; HYBRID PROTEIN; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; RETINOIC ACID RECEPTOR ALPHA;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL MATURATION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; FUSION GENE; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; RECEPTOR SENSITIVITY; SIGNAL TRANSDUCTION;

EID: 0036464602     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.3.1014     Document Type: Article

References (47)

1. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
2. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia
3. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins
4. 3) in the treatment of acute promyelocytic leukemia (APL), II. Clinical efficacy and pharmacokinetics in relapsed patients
5. 15/17 translocation a consistent chromosomal change in acute promyelocytic leukemia
6. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus
7. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR
8. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML
9. Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia
10. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia
11. Reduced retinoic acid sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia
12. Role of the histone deacetylase complex in acute promyelocytic leukaemia
13. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia
14. Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemia
15. 3 exerts dose-dependent dual effects on APL cells
16. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia
17. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia
18. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells
19. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells
20. Combined effect of all-trans retinoic acid and arsenic in acute promyelocytic leukemia cells in vitro and in vivo
21. Signal transduction from the cell surface to the nucleus through the phosphorylation of transcription factors
22. Induction of lysozyme activity by adenosine 3′:5′ cyclic mono-phosphate in cultured mouse myeloid leukemic cells
23. Site-selective cAMP analogs at micromolar concentrations induce growth arrest and differentiation of acute promyelocytic, chronic myelocytic, and acute lymphocytic human leukemia cell lines
24. Two distinctly regulated events, priming and triggering, during retinoid-induced maturation and resistance of NB4 promyelocytic leukemia cell line
25. A sustained increase in the endogenous level of cAMP reduces the retinoid concentration required for APL cell maturation to near physiological levels
26. RAR-independent RXR signaling induces t(15;17) leukemia cell maturation
27. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3)
28. Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger-retinoic acid receptor-alpha fusion protein
29. A mutated PML/RARA found in the retinoid maturation resistant NB4 subclone, NB4-R2, blocks RARA and wild-type PML/RARA transcriptional activities
30. Treatment of acute promyelocytic leukemia with arsenic compounds: In vitro and in vivo studies
31. A retinoid acid "resistant" t(15;17) acute promyelocytic leukemia cell line: isolation, morphological, immunological, and molecular features
32. The p21 Cdk-interacting protein Cip 1 is a potent inhibitor of G 1 cyclin-dependent kinases
33. p21 is a universal inhibitor of cyclin kinases
34. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
35. 1 arrest and apoptosis
36. Induction of WAF1/CIP1 by a p53-independent pathway
37. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53
38. Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: A comparison with conventional dosage
39. Differentiation-related changes in the cell cycle traverse
40. New developments in the therapy of acute myelocytic leukemia, II. differentiation therapy revisited
41. 2/M cell cycle transition
42. Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells
43. Lineage-specific regulation of cell cycle gene expression in differentiating myeloid cells
44. Cyclins, cyclin-dependent kinase and Cdk inhibitors: Implications in cell cycle control and cancer
45. Exploring (novel) gene expression during retinoid-induced maturation and cell death of acute promyelocytic leukemia
46. Preliminary study on the role of the cAMP-PKA pathway during retinoic acid-induced APL cell differentiation
47. Modulation of apoptosis of proliferating and differentiating HL-60 cells by protein kinase inhibitors: Suppression of PKC or PKA differently affects cell differentiation and apoptosis